Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties.
The development of non-peptide agonists for peptide hormone receptors would markedly expand the treatment options for a large number of diseases. However, difficulty in identifying non-peptide molecules which possess intrinsic activity has been a major obstacle in achieving this goal. At present, most of the known non-peptide ligands for peptide hormone receptors appear in standard functional assays to be antagonists. Here, we report that a constitutively active mutant of the human cholecystokinin-B/gastrin receptor, Leu325 --> Glu, offers the potential to detect even trace agonist activity of ligands which, at the wild type receptor isoform, appear to lack efficacy. The enhanced functional sensitivity of the mutant receptor enabled us to detect intrinsic activity of L-365,260, an established non-peptide antagonist for the cholecystokinin-B/gastrin receptor. Extending from this observation, we were able to demonstrate that minor structural modifications could convert L-365, 260 into either: (i) an agonist or (ii) an inverse agonist (attenuates ligand-independent signaling). The ability to confer functional activity to small non-peptide ligands suggests that the properties of endogenous peptide hormones can be mimicked, and even extended, by considerably less complex molecules.
Beinborn
M
M
Department of Medicine and Center for Gastroenterology Research on Absorptive and Secretory Processes, Tupper Research Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Quinn
S M
SM
Kopin
A S
AS
D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D001570:Benzodiazepinones / Q000737:chemistry / Q000494:pharmacology; D001667:Binding, Competitive; D019556:COS Cells; D006727:Hormone Antagonists / Q000494:pharmacology; D007295:Inositol Phosphates / Q000378:metabolism; D015394:Molecular Structure; D009154:Mutation / Q000235:genetics; D010455:Peptides / Q000378:metabolism; D010671:Phenylurea Compounds / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics*; D015398:Signal Transduction / Q000502:physiology; D014162:Transfection / Q000235:genetics
D001570:Benzodiazepinones; D006727:Hormone Antagonists; D007295:Inositol Phosphates; D010455:Peptides; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; D001569:Benzodiazepines; C087260:YM 022; C090649:L 740093; C058121:L 365260